Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma
← catalyst calendarNCT06334991 · readout ≤ 438 d
Sponsored by ImmunityBio, Inc. (industry) · IBRX — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
20actual
Sites
3
Country
South Africa
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-23 | actual | When the study began enrolling |
| Primary completion | Oct 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Hodgkin Lymphoma Refractory/ Relapsed
Intervention
- Biological: CD19 t-haNK — also filed as Rituximab
Primary outcomes
what the primary-completion date above is the date OFOverall safety evaluation in combining CD19 t haNK as a single agent with rituximab
measured 30 days
Incidence of treatment-emergent AEs (TEAEs) and serious AEs (SAEs) graded using the National Cancer Institute (NCI) CTCAE Version 5.0.Clinically important changes in safety laboratory tests and vital signs.
measured 12 months
Permalink · IBRX's whole pipeline · Catalyst calendar · Every registered study · What changed